Hemostatic molecular markers before the onset of disseminated intravascular coagulation.
We retrospectively measured various hemostatic markers in 240 patients with disseminated intravascular coagulation (DIC) before the onset of DIC and in 110 non-DIC patients, and examined their usefulness for the diagnosis of pre-DIC. Changes in prothrombin time ratio and fibrinogen levels were not significant before the onset of DIC. The plasma levels of fibrinogen and fibrin degradation products before the onset of DIC were increased and the platelet count was gradually reduced in nonleukemic patients; these changes were already significant in the non-DIC state. The plasma levels of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer, and soluble fibrin monomer (sFM) were increased before the onset of DIC. In leukemic patients, the plasma levels of sFM on day 5, those of TAT on day 3, and D-dimer on day 1, were significantly increased before the onset of DIC. The levels of most hemostatic markers 7 days before the onset of DIC were not different from those observed in the non-DIC state. In nonleukemic patients, only D-dimer, sFM, and TAT levels were significantly increased 7 days before the onset of DIC compared with values in the non-DIC state. The positive rate of hemostatic markers for the diagnosis of DIC, TAT, and PPIC were high during the pre-DIC and non-DIC groups. The plasma levels of sFM and D-dimer were low in non-DIC and increased gradually during the pre-DIC state. These findings suggest that hemostatic molecular markers such as sFM, D-dimer, and TAT are useful for the diagnosis of pre-DIC, although their cutoff values were different among various diseases.
Wada
H
H
Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Mie-ken, Japan.
Sakuragawa
N
N
Mori
Y
Y
Takagi
M
M
Nakasaki
T
T
Shimura
M
M
Hiyoyama
K
K
Nisikawa
M
M
Gabazza
E C
EC
Deguchi
K
K
Kazama
M
M
Shiku
H
H
D000933:Antifibrinolytic Agents / Q000097:blood / Q000378:metabolism; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood*; D004211:Disseminated Intravascular Coagulation / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000378:metabolism; D005341:Fibrinolysin / Q000378:metabolism; D006487:Hemostasis; D006801:Humans; D007239:Infections / Q000150:complications; D007938:Leukemia / Q000150:complications; D009369:Neoplasms / Q000150:complications; D010447:Peptide Hydrolases / Q000032:analysis; D010976:Platelet Count; D011517:Prothrombin Time; D012189:Retrospective Studies; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C011468:fibrinmonomer; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases; D005341:Fibrinolysin